Comparison of treatment benefit and outcome in women versus men with chronic heart failure (from the Valsartan Heart Failure Trial) - 21/08/11
Doi : 10.1016/j.amjcard.2004.10.026
Silja K. Majahalme, MD, PhD a, b, ⁎ 
, Lawrence Baruch, MD c, Nora Aknay, BSc d, Liselotte Goedel-Meinen, MD e, Monika Hofmann, MD e, Allen Hester, PhD d, Margaret Forney Prescott, PhD d, Nancy Feliciano, MD d
, Lawrence Baruch, MD c, Nora Aknay, BSc d, Liselotte Goedel-Meinen, MD e, Monika Hofmann, MD e, Allen Hester, PhD d, Margaret Forney Prescott, PhD d, Nancy Feliciano, MD dfor the Val-HeFT Study Investigators
a Tampere University, Tampere, Finland
b Appleton Heart Institute, Appleton, Wisconsin
c Bronx Veterans Affairs Medical Center, New York, New York
d Novartis Pharmaceuticals Corporation, East Hanover, New Jersey
e Deutsches Herzzentrum, Technische Universitat München, Munich, Germany
*Dr. Majahalme's address is: Appleton Heart Institute, 1818 N. Meade Street, Appleton, Wisconsin 54911
Résumé |
The comparison of treatment effect and co-morbidity between the genders in the Valsartan Heart Failure Trial showed equal benefit of treatment in men and women. Co-morbidities, such as diabetes and coronary artery disease, increased nonfatal cardiac morbidity more in women than in men.
Le texte complet de cet article est disponible en PDF.© 2005
Excerpta Medica Inc. Tous droits réservés.
Vol 95 - N° 4
P. 529-532 - février 2005 Retour au numéro
Article précédent
- Time–frequency analysis of the surface electrocardiogram for monitoring antiarrhythmic drug effects in atrial fibrillation
- Daniela Husser, Martin Stridh, Leif Sornmo, Christoph Geller, Helmut U. Klein, S. Bertil Olsson, Andreas Bollmann
- Renal handling of endothelin in patients with chronic heart failure
- Abdul Al-Hesayen, John D. Parker
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?